Effects of Inhibiting Early Inflammation in Kidney Transplant Patients
Public ClinicalTrials.gov record NCT02495077. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized Controlled Trial of Infliximab (Remicade®) Induction Therapy for Deceased Donor Kidney Transplant Recipients (CTOT-19)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
During transplant surgery, there is a period of time when a donated kidney is removed from a donor's body and stored until the time of the transplant surgery. The storage procedure results in buildup of various proteins within the kidney that can injure the donated kidney after it is transplanted. One of these proteins is tumor necrosis factor-alpha (TNF-alpha). The purpose of this study is to evaluate whether taking infliximab, which blocks tumor necrosis factor alpha (TNF-alpha), just prior to transplant surgery, along with usual transplant medicines will protect the donated kidney from damage caused by TNF-alpha and help keep the transplanted kidney healthy for a longer period of time.
Study identification
- NCT ID
- NCT02495077
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 290 participants
Conditions and interventions
Conditions
Interventions
- Infliximab Biological
- Methylprednisolone Drug
- Mycophenolate Mofetil Drug
- Tacrolimus Drug
- Thymoglobulin® Biological
- Acetaminophen Drug
- Loratadine Drug
- Placebo for Infliximab Biological
- Prednisone Drug
- Diphenhydramine Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2, 2015 (Actual)
- Primary completion
- Jul 23, 2021 (Actual)
- Completion
- Jul 23, 2021 (Actual)
- Last update posted
- Sep 24, 2026
2015 – 2021
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| University of California, Los Angeles | Los Angeles | California | 90024 | — |
| University of California, San Francisco | San Francisco | California | 94143 | — |
| Yale University | New Haven | Connecticut | 06511 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| University of Maryland | Baltimore | Maryland | 21201 | — |
| Johns Hopkins University | Baltimore | Maryland | 21287 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Washington University School of Medicine in St. Louis | St Louis | Missouri | 63110 | — |
| Mount Sinai Medical Center | New York | New York | 10029 | — |
| Cleveland Clinic | Cleveland | Ohio | 44106 | — |
| University Hospitals of Cleveland | Cleveland | Ohio | 44106 | — |
| University of Wisconsin | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02495077, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 24, 2026 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02495077 live on ClinicalTrials.gov.